Drug may improve outcomes in mild stroke patients, save $200 million annually

Feb 09, 2011

Treating mild strokes with the clot-busting drug approved for severe stroke could reduce the number of patients left disabled and save $200 million a year in disability costs, according to a study presented at the American Stroke Association's International Stroke Conference 2011.

Researchers analyzed hospital records from 437 patients diagnosed with mild ischemic stroke at 16 sites in the Greater Cincinnati/Northern Kentucky region in 2005. The patients arrived at the hospital within the 3.5 hours, well within the 4.5 hour window for treatment with intravenous tissue plasminogen activator (tPA).

The federal government has approved the clot-busting drug for strokes caused by blood clots, known as , which accounts for 87 percent of all strokes. It's the only acute stroke drug that can reduce disability but remains unproven for treating mild stroke.

"Currently, there is no standard of treatment for patients with the mildest strokes, even if they come into the emergency department quickly enough for intravenous tPA, the only proven treatment for a more serious stroke," said Pooja Khatri, M.D., lead researcher of the study and associate professor in the Department of Neurology and director of acute stroke at the University of Cincinnati Academic Health Center in Ohio.

"The pivotal randomized trials that proved tPA's usefulness excluded mild stroke patients because it was thought that they generally did well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit," she said.

Only four of the mild stroke patients (less than 1 percent) received tPA. The researchers identified 150 of the remaining patients as likely candidates for the drug if the mildness of their stroke was disregarded as a reason to deny them tPA treatment.

Based on the findings, the researchers then excluded those with baseline disability (estimated at 37 percent) and assumed that 8 percent to 13 percent of the remaining mild would regain independence after their stroke if tPA was as effective as it was in more serious cases.

Extrapolating to the U.S. population, the researchers said that if tPA proves effective, 2,176 to 3,761 fewer patients would be disabled from mild each year — saving an estimated $200 million in disability expenditures.

In the last five years, researchers conducting several studies have found that about a third of patients who experienced so-called mild strokes remained disabled three months after initial hospitalization.

"It was believed that patients with milder strokes would recover from these events," Khatri said. "These findings raise the question of whether the mildest strokes should be treated with intravenous tPA."

Explore further: Risk of antibiotic overuse in aged care settings

add to favorites email to friend print save as pdf

Related Stories

Study shows ultrasound and tPA effective for stroke

Feb 19, 2009

An experimental therapy using tiny bubbles activated by transcranial Doppler (TCD) ultrasound combined with the clot busting drug tissue plasminogen activator (tPA) is more effective than tPA alone in treating patients suffering ...

Recommended for you

Supermaterial gives rejected drugs a new chance

11 hours ago

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

User comments : 0